Cargando…
Changes in correlation between promoter methylation and gene expression in cancer
BACKGROUND: Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Aberrant promoter methylation is considered a hallmark of cancer involved in silencing of tumor suppressor genes and activation of onco...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625954/ https://www.ncbi.nlm.nih.gov/pubmed/26510534 http://dx.doi.org/10.1186/s12864-015-1994-2 |
_version_ | 1782398052542185472 |
---|---|
author | Moarii, Matahi Boeva, Valentina Vert, Jean-Philippe Reyal, Fabien |
author_facet | Moarii, Matahi Boeva, Valentina Vert, Jean-Philippe Reyal, Fabien |
author_sort | Moarii, Matahi |
collection | PubMed |
description | BACKGROUND: Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Aberrant promoter methylation is considered a hallmark of cancer involved in silencing of tumor suppressor genes and activation of oncogenes. However, recent studies have also challenged the simple model of gene expression control by promoter methylation in cancer, and the precise mechanism of and role played by changes in DNA methylation in carcinogenesis remains elusive. RESULTS: Using a large dataset of 672 matched cancerous and healthy methylomes, gene expression, and copy number profiles accross 3 types of tissues from The Cancer Genome Atlas (TCGA), we perform a detailed meta-analysis to clarify the interplay between promoter methylation and gene expression in normal and cancer samples. On the one hand, we recover the existence of a CpG island methylator phenotype (CIMP) with prognostic value in a subset of breast, colon and lung cancer samples, where a common subset of promoter CGIs hypomethylated in normal samples become hypermethylated. However, this hypermethylation is not accompanied by a decrease in expression of the corresponding genes, which are already lowly expressed in the normal genes. On the other hand, we identify tissue-specific sets of genes, different between normal and cancer samples, whose inter-individual variation in expression is significantly correlated with the variation in methylation of the 3’ flanking regions of the promoter CGIs. These subsets of genes are not the same in the different tissues, nor between normal and cancerous samples, but transcription factors are over-represented in all subsets. CONCLUSION: Our results suggest that epigenetic reprogramming in cancer does not contribute to cancer development via direct inhibition of gene expression through promoter hypermethylation. It may instead modify how the expression of a few specific genes, particularly transcription factors, are associated with DNA methylation variations in a tissue-dependent manner. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-015-1994-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4625954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46259542015-10-30 Changes in correlation between promoter methylation and gene expression in cancer Moarii, Matahi Boeva, Valentina Vert, Jean-Philippe Reyal, Fabien BMC Genomics Research Article BACKGROUND: Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Aberrant promoter methylation is considered a hallmark of cancer involved in silencing of tumor suppressor genes and activation of oncogenes. However, recent studies have also challenged the simple model of gene expression control by promoter methylation in cancer, and the precise mechanism of and role played by changes in DNA methylation in carcinogenesis remains elusive. RESULTS: Using a large dataset of 672 matched cancerous and healthy methylomes, gene expression, and copy number profiles accross 3 types of tissues from The Cancer Genome Atlas (TCGA), we perform a detailed meta-analysis to clarify the interplay between promoter methylation and gene expression in normal and cancer samples. On the one hand, we recover the existence of a CpG island methylator phenotype (CIMP) with prognostic value in a subset of breast, colon and lung cancer samples, where a common subset of promoter CGIs hypomethylated in normal samples become hypermethylated. However, this hypermethylation is not accompanied by a decrease in expression of the corresponding genes, which are already lowly expressed in the normal genes. On the other hand, we identify tissue-specific sets of genes, different between normal and cancer samples, whose inter-individual variation in expression is significantly correlated with the variation in methylation of the 3’ flanking regions of the promoter CGIs. These subsets of genes are not the same in the different tissues, nor between normal and cancerous samples, but transcription factors are over-represented in all subsets. CONCLUSION: Our results suggest that epigenetic reprogramming in cancer does not contribute to cancer development via direct inhibition of gene expression through promoter hypermethylation. It may instead modify how the expression of a few specific genes, particularly transcription factors, are associated with DNA methylation variations in a tissue-dependent manner. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-015-1994-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-28 /pmc/articles/PMC4625954/ /pubmed/26510534 http://dx.doi.org/10.1186/s12864-015-1994-2 Text en © Moarii et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Moarii, Matahi Boeva, Valentina Vert, Jean-Philippe Reyal, Fabien Changes in correlation between promoter methylation and gene expression in cancer |
title | Changes in correlation between promoter methylation and gene expression in cancer |
title_full | Changes in correlation between promoter methylation and gene expression in cancer |
title_fullStr | Changes in correlation between promoter methylation and gene expression in cancer |
title_full_unstemmed | Changes in correlation between promoter methylation and gene expression in cancer |
title_short | Changes in correlation between promoter methylation and gene expression in cancer |
title_sort | changes in correlation between promoter methylation and gene expression in cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625954/ https://www.ncbi.nlm.nih.gov/pubmed/26510534 http://dx.doi.org/10.1186/s12864-015-1994-2 |
work_keys_str_mv | AT moariimatahi changesincorrelationbetweenpromotermethylationandgeneexpressionincancer AT boevavalentina changesincorrelationbetweenpromotermethylationandgeneexpressionincancer AT vertjeanphilippe changesincorrelationbetweenpromotermethylationandgeneexpressionincancer AT reyalfabien changesincorrelationbetweenpromotermethylationandgeneexpressionincancer |